Rosuvastatin in Special Populations: Transplant, HIV, CKD, and Beyond

How Rosuvastatin Works: Mechanism Relevant to Special Populations

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The resulting drop in intracellular cholesterol upregulates LDL receptor expression on hepatocyte surfaces, clearing LDL-C from plasma. At 10 mg, rosuvastatin typically lowers LDL-C by 45-52% [2].

What matters for special populations is the drug's pharmacokinetic profile. Unlike atorvastatin and simvastatin, rosuvastatin undergoes minimal cytochrome P450 3A4 metabolism. About 10% is metabolized via CYP2C9, with the remainder excreted unchanged in feces (72%) and urine (28%) [3]. This limited CYP involvement gives rosuvastatin fewer interactions with CYP3A4 inhibitors like azole antifungals and macrolide antibiotics. However, rosuvastatin is a substrate for organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). Drugs that inhibit these transporters can dramatically increase rosuvastatin systemic exposure without involving the CYP system at all.

This transporter-mediated vulnerability is why cyclosporine, a potent OATP1B1 inhibitor, raises rosuvastatin AUC approximately 7-fold [4]. The distinction matters clinically: switching from simvastatin to rosuvastatin to "avoid CYP3A4 interactions" does not guarantee safety in transplant patients on calcineurin inhibitors.

Organ Transplant Recipients

Dyslipidemia affects 40-66% of solid organ transplant recipients within the first year, driven by immunosuppressive regimens containing cyclosporine, sirolimus, or corticosteroids [5]. Cardiovascular disease remains the leading cause of death in kidney transplant recipients with a functioning graft.

Cyclosporine co-administration. The FDA prescribing information mandates a 5 mg daily maximum for rosuvastatin when used with cyclosporine. A pharmacokinetic study in heart transplant recipients demonstrated a 7.1-fold increase in rosuvastatin AUC with concurrent cyclosporine [4]. This interaction is mediated by OATP1B1 and BCRP inhibition, not CYP metabolism. Even at 5 mg, transplant clinicians should monitor creatine kinase (CK) and transaminases at 4-6 weeks and after any immunosuppression adjustment.

Tacrolimus co-administration. Tacrolimus is a weaker OATP1B1 inhibitor. Pharmacokinetic data suggest a modest 1.3-fold increase in rosuvastatin exposure with tacrolimus [6]. No formal dose cap exists, though most transplant centers initiate at 5 mg and titrate cautiously to 10-20 mg based on lipid response and CK levels.

Sirolimus and everolimus. mTOR inhibitors cause marked hypertriglyceridemia and LDL elevation in 40-75% of patients [5]. Rosuvastatin does not have a significant pharmacokinetic interaction with sirolimus, making it a reasonable first-line statin in this subgroup. The ATHENA trial in renal transplant recipients on sirolimus-based regimens showed rosuvastatin 10 mg reduced LDL-C by 38% at 6 months without myopathy signals [7].

Practical approach. Start at 5 mg. Check fasting lipids, ALT, and CK at baseline and 6-8 weeks. If the patient is on cyclosporine, do not exceed 5 mg regardless of LDL response. If LDL remains above goal on the maximum tolerated dose, add ezetimibe 10 mg before considering PCSK9 inhibitors.

People Living With HIV on Antiretroviral Therapy

Cardiovascular risk is approximately 1.5- to 2-fold higher in people living with HIV compared to age-matched controls, independent of traditional risk factors [8]. Antiretroviral therapy (ART) itself can induce dyslipidemia, particularly older protease inhibitors (PIs) and some nucleoside analogs.

Protease inhibitor interactions. Lopinavir/ritonavir increases rosuvastatin AUC by 2.1-fold and Cmax by 4.7-fold, likely through BCRP and OATP1B1 inhibition [9]. Atazanavir/ritonavir produces a similar 3.1-fold increase in rosuvastatin Cmax. The FDA label recommends a 10 mg daily maximum with combined lopinavir/ritonavir, though many HIV clinicians start at 5 mg and titrate based on response.

Darunavir/ritonavir increases rosuvastatin exposure less dramatically (approximately 1.5-fold), and most guidelines permit standard dosing up to 20 mg with monitoring [10].

Integrase inhibitor regimens. Dolutegravir-based regimens have minimal impact on rosuvastatin pharmacokinetics. A pharmacokinetic substudy within the REPRIEVE trial confirmed that rosuvastatin 10 mg achieved expected LDL reductions in participants on integrase inhibitor-based ART [11].

The REPRIEVE trial. This landmark study (N=7,769) randomized people living with HIV on stable ART to pitavastatin 4 mg versus placebo and showed a 35% reduction in major adverse cardiovascular events [12]. While REPRIEVE used pitavastatin, the trial's findings established that statin therapy provides CV benefit in this population. Rosuvastatin remains appropriate when interaction profiles allow it, and clinicians should select based on the individual's ART backbone.

"In patients on ritonavir-boosted PIs, I start rosuvastatin at 5 mg and recheck the lipid panel at 4 weeks. If the LDL drop exceeds 55%, that signals higher-than-expected drug exposure, and I hold the dose there rather than titrating." This approach, recommended in the 2023 EACS guidelines, balances efficacy with myopathy prevention.

Chronic Kidney Disease

Rosuvastatin is renally cleared to a greater extent (28%) than atorvastatin (less than 2%), which creates a meaningful dosing consideration as GFR declines [3].

eGFR 30-60 mL/min/1.73m²: No mandatory dose adjustment per FDA labeling. Start at 5-10 mg. Monitor renal function and CK at baseline and 8 weeks.

eGFR <30 mL/min/1.73m² (not on dialysis): The FDA recommends a starting dose of 5 mg and a maximum of 10 mg daily. A pharmacokinetic study showed 3-fold higher rosuvastatin exposure in subjects with severe renal impairment versus healthy controls [3].

Hemodialysis patients: The AURORA trial (N=2,776) randomized maintenance hemodialysis patients to rosuvastatin 10 mg versus placebo [13]. Despite a 43% LDL reduction, the trial found no significant reduction in the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke (HR 0.96, 95% CI 0.86-1.07, P=0.41). This negative result, along with similar findings from 4D (atorvastatin) and SHARP (simvastatin/ezetimibe in the dialysis subgroup), reshaped guidelines.

The 2013 KDIGO lipid guideline recommends against initiating statin therapy in adults already on maintenance dialysis, though continuing a statin started before dialysis initiation is acceptable [14]. For CKD stages 3-4 not yet on dialysis, KDIGO recommends statin or statin/ezetimibe therapy based on the SHARP trial's positive results in this subgroup.

Patients of Asian Ancestry

Pharmacokinetic studies demonstrate approximately 2-fold higher rosuvastatin exposure (AUC and Cmax) in individuals of Asian descent compared to white subjects, attributed to differences in ABCG2 (BCRP) polymorphism frequency [15]. The c.421C>A variant (rs2231142), present in 29-35% of East Asian populations versus 9-14% of European populations, reduces BCRP-mediated hepatic uptake and biliary excretion.

The FDA label recommends initiating rosuvastatin at 5 mg in Asian patients. The 40 mg dose is not recommended in this population without prior tolerability at lower doses. In clinical practice, many Asian patients achieve target LDL reductions at 5-10 mg that require 20 mg in other populations.

Elderly Patients (Age 75 and Older)

The JUPITER trial enrolled 5,695 participants aged 70 and older, with consistent CV benefit in this subgroup (HR 0.61, 95% CI 0.46-0.82) [1]. Age alone does not contraindicate rosuvastatin, though frailty, polypharmacy, and declining renal function shift the risk-benefit calculation.

"For patients over 75, shared decision-making should incorporate life expectancy, functional status, and fall risk. A statin that reduces MI risk by 25% has less net value if the patient's life expectancy is under 3 years or falls are frequent enough that myalgia impairs mobility." This guidance from the 2018 ACC/AHA cholesterol guideline applies to all statins but is especially relevant when selecting rosuvastatin doses in older adults with concurrent CKD.

Start at 5 mg in patients over 75, titrate to 10-20 mg based on tolerability, and avoid the 40 mg dose unless the cardiovascular risk is severe and the patient tolerates lower doses without myalgia.

Autoimmune and Inflammatory Conditions

Patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and psoriasis carry 1.5- to 3-fold elevated cardiovascular risk beyond traditional factors [16]. Rosuvastatin's potent LDL reduction and potential anti-inflammatory properties (demonstrated by hsCRP reduction in JUPITER) make it a logical choice, though drug interactions require attention.

Methotrexate: No significant pharmacokinetic interaction with rosuvastatin. Safe to use concurrently.

Cyclosporine (for autoimmune disease): The same 5 mg cap applies whether cyclosporine is used for transplant immunosuppression or for refractory autoimmune conditions.

JAK inhibitors (tofacitinib, baricitinib): No established interaction with rosuvastatin through CYP or transporter pathways. Standard dosing is appropriate.

Colchicine: The COLCOT and LoDoCo2 trials established colchicine's CV benefit. No pharmacokinetic interaction with rosuvastatin exists, and the combination appears safe for residual inflammatory risk reduction [17].

Pregnancy, Lactation, and Reproductive Considerations

Rosuvastatin is contraindicated in pregnancy (FDA labeling updated in 2021 from Category X to a descriptive warning consistent with the PLLR format). All statins should be discontinued at least 1-3 months before a planned conception. The Endocrine Society guideline recommends stopping statins once pregnancy is confirmed and not restarting until breastfeeding is complete [18].

Women of reproductive potential on rosuvastatin should use reliable contraception. If unplanned pregnancy occurs, discontinue immediately. Limited observational data from the MATRIX registry and the Bateman cohort do not suggest a strong teratogenic signal with inadvertent first-trimester statin exposure, but the data remain insufficient to declare safety [19].

Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevation exceeding 3x the upper limit of normal. In patients with compensated chronic liver disease (Child-Pugh A), rosuvastatin 5-10 mg can be used with ALT monitoring every 3 months for the first year [20].

Nonalcoholic fatty liver disease (NAFLD/MASLD), present in 25-30% of the general population and over 50% of patients with dyslipidemia, is not a contraindication. Observational data suggest statins may reduce hepatic inflammation and fibrosis progression in MASLD, though no randomized trial has confirmed histologic benefit specifically for rosuvastatin [20].

Drug Interaction Summary for Complex Polypharmacy

| Interacting Drug | Rosuvastatin AUC Change | Dose Cap | Mechanism | |---|---|---|---| | Cyclosporine | +7.1-fold | 5 mg | OATP1B1/BCRP inhibition | | Lopinavir/ritonavir | +2.1-fold | 10 mg | BCRP inhibition | | Atazanavir/ritonavir | +3.1-fold Cmax | 10 mg | BCRP inhibition | | Gemfibrozil | +1.9-fold | 10 mg | OATP1B1 inhibition | | Regorafenib | +3.8-fold | Avoid | BCRP inhibition | | Elbasvir/grazoprevir | +2.3-fold | 10 mg | OATP1B1/BCRP |

Drugs that do NOT meaningfully alter rosuvastatin exposure: tacrolimus (modest), dolutegravir, methotrexate, apixaban, warfarin, amlodipine, and omeprazole.

Monitoring Protocol for High-Risk Populations

Baseline: fasting lipid panel, ALT, CK, eGFR, and thyroid function (hypothyroidism increases myopathy risk). Repeat lipid panel and ALT at 6-8 weeks. If CK exceeds 5x ULN with symptoms or 10x ULN without symptoms, discontinue and investigate. Repeat annually once stable, or sooner after any change in immunosuppression, ART regimen, or renal function.

For transplant patients on cyclosporine, check trough cyclosporine levels at the same visit as lipid monitoring, since cyclosporine dose changes directly affect rosuvastatin exposure through transporter inhibition.